MERSANA THERAPEUTICS ($NASDAQ:MRSN) reported their second quarter FY2023 earnings results on June 30 2023, with total revenue of USD 10.7 million, a 148.8% increase from the same period in the previous year. Net income stood at USD -54.3 million, an improvement from the -52.2 million reported a year ago.
Analyzing MERSANA THERAPEUTICS fundamentals with GoodWhale reveals that the company is strong in terms of assets and growth but weak in dividends and profitability. The company is classified as a “cheetah”, meaning it achieved high revenue or earnings growth but is considered less stable due to lower profitability. This could make it interesting to investors looking for higher-risk opportunities with potential for high returns. However, it is important to take into account the health score of MERSANA THERAPEUTICS, which is 3/10 with regard to its cash flows and debt. This implies that the company is less likely to sustain future operations in times of crisis. Therefore, investors should exercise caution when considering investing in MERSANA THERAPEUTICS as there is a risk of financial losses. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Mersana Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Mersana Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Mersana Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Mersana Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s lead product candidate, XMT-1536, is in clinical development for the treatment of solid tumors. Mersana has two other ADC product candidates in development, XMT-1522 and XMT-1592. Mersana’s main competitors are Sensei Biotherapeutics Inc, IMV Inc, and Immunome Inc. These companies are also focused on developing cancer therapies, including ADCs.
– Sensei Biotherapeutics Inc ($NASDAQ:SNSE)
Sensei Biotherapeutics Inc is a clinical-stage immuno-oncology company. The company is focused on developing and commercializing its proprietary platform of off-the-shelf, anti-sense oligonucleotide therapeutics to treat a range of solid tumors and hematologic malignancies.
IMV Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of cancer immunotherapies and other immune modulating agents. Its product candidates include DPX-Survivac, T cell Receptor, and Antibody Programs. The company was founded by Frederic Ors on December 15, 1999 and is headquartered in Halifax, Canada.
Immunome Inc is a clinical stage biopharmaceutical company that focuses on the development of monoclonal antibody therapeutics for the treatment of cancer. The company has a market cap of 56.88M as of 2022 and a return on equity of -65.38%. The company’s focus on the development of monoclonal antibody therapeutics for the treatment of cancer makes it a unique player in the biopharmaceutical industry. The company’s clinical stage status also makes it a high-risk investment, but one that could offer high rewards if the company’s products are successful in the marketplace.
Mersana Therapeutics reported their second quarter of FY2023 earnings, showing total revenue of USD 10.7 million, a 148.8% year-over-year increase. Net income was -USD 54.3 million, a slight improvement compared to FY2022’s -USD 52.2 million. For potential investors, this indicates that the company is continuing to grow with revenue and profitability increasing overall.
However, investors should be aware that net income remains in the red and will need to be monitored carefully. Overall, Mersana Therapeutics looks like a company with potential that requires further research for investors interested in pursuing it.